Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2017, Article ID 8417249, 15 pages
https://doi.org/10.1155/2017/8417249
Review Article

Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis

1Mapi, Boston, MA, USA
2Pfizer Inc., Groton, CT, USA
3Pfizer Inc., New York City, NY, USA

Correspondence should be addressed to Gene Wallenstein; moc.rezifp@nietsnellaw.eneg

Received 28 July 2016; Accepted 24 November 2016; Published 9 March 2017

Academic Editor: Tim Jansen

Copyright © 2017 Evelien Bergrath et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary Table 1 provides an overview of the patient characteristics across all the identified RCTs, Supplementary Figure 1. ACR20 response at 24 weeks (monotherapy) - Odds ratios and 95% CIs for TOF 5 mg and TOF 10 mg versus other treatments, as obtained with random effects NMA, Supplementary Figure 2. ACR50 response at 24 weeks (monotherapy) – Odds ratios and 95% CIs for TOF 5 mg and TOF 10 mg versus other treatments, as obtained with random effects NMA, Supplementary Figure 3. ACR70 response at 24 weeks (monotherapy) – Odds ratios and 95% CIs for TOF 5 mg and TOF 10 mg versus other treatments, as obtained with random effects NMA, Supplementary Figure 4. Withdrawals due to adverse events (Monotherapy) – Odds ratios and 95% CIs for TOF 5 mg and TOF 10 mg versus other treatments, as obtained with random effects NMA, Supplementary Figure 5. ACR20 response at 24 weeks (combination therapy) - Odds ratios and 95% Cls for TOF 5 mg + DMARDs and TOF 10 mg + DMARDs versus other treatments, as obtained with random effects NMA, Supplementary Figure 6. ACR50 response at 24 weeks (combination therapy) - Odds ratios and 95% Cls for TOF 5 mg + DMARDs and TOF 10 mg + DMARDs versus other treatments, as obtained with random effects NMA, Supplementary Figure 7. ACR70 response at 24 weeks (combination therapy) - Odds ratios and 95% Cls for TOF 5 mg + DMARDs and TOF 10 mg + DMARDs versus other treatments, as obtained with random effects NMA, Supplementary Figure 8. HAQ-DI at 24 weeks (Combination therapies) Modelled change from baseline and 95% CIs for all treatments, as obtained with random effects NMA, Supplementary Figure 9. Withdrawals due to adverse events (Combination therapy) - Odds ratios and 95% Cls for TOF 5 mg + DMARDs and TOF 10 mg + DMARDs versus other treatments, as obtained with random effects NMA, Supplementary Figure 10. ACR20 response at 24 weeks (MTX combination therapy) – Odds ratios and 95% CIs for TOF 5 mg + MTX and TOF 10 mg + MTX versus other treatments, as obtained with random effects NMA, Supplementary Figure 11. ACR50 response at 24 weeks (MTX combination therapy) – Odds ratios and 95% CIs for TOF 5 mg + MTX and TOF 10 mg + MTX versus other treatments, as obtained with random effects NMA, Supplementary Figure 12. ACR70 response at 24 weeks (MTX combination therapy) – Odds ratios and 95% CIs for TOF 5 mg + MTX and TOF 10 mg + MTX versus other treatments, as obtained with random effects NMA, Supplementary Figure 13. HAQ-DI at 24 weeks (MTX combination therapies) - Modelled change from baseline and 95% CIs for all treatments, as obtained with random effects NMA, Supplementary Figure 14. Withdrawals due to adverse events (MTX combination therapy) – Odds ratios and 95% CIs for TOF 5 mg + MTX and TOF 10 mg + MTX versus other treatments, as obtained with random effects NMA.

  1. Supplementary Material